MacroGenics saw the highest growth of 0.99% in patent filings in June and 1.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.74% and grants by 0.32%. GlobalData’s DataBook provides a comprehensive analysis of MacroGenics’s patent filings and grants. Buy the databook here.
MacroGenics has been focused on protecting inventions in European Patent Office(EPO) with six publications in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent filings and grants with nearly 40% filings and 25% grants. The European Patent Office(EPO), United States(US), Australia(AU), and Spain(ES) patent Office are among the top ten patent offices where MacroGenics is filings its patents. Among the top granted patent authorities, MacroGenics has 25% of its grants in European Patent Office(EPO), 25% in Australia(AU) and 25% in Spain(ES).
Regeneron Pharmaceuticals and Amgen could be the strongest competitors for MacroGenics
Patents related to rare diseases and climate change lead MacroGenics's portfolio
MacroGenics has the highest number of patents in rare diseases followed by, climate change. For rare diseases, nearly 67% of patents were filed and 100% of patents were granted in Q2 2024.
Carcinomas related patents lead MacroGenics portfolio followed by non-small cell lung cancer, and head and neck cancer
MacroGenics has highest number of patents in carcinomas followed by non-small cell lung cancer, head and neck cancer, uterine cancer, and lymphoma. For carcinomas, nearly 2% of patents were filed and 50% of patents were granted in Q2 2024.
For comprehensive analysis of MacroGenics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.